Overview

A Study to Assess the Safety, Tolerability and Effectiveness of MT-0814 for the Treatment of Age-related Macular Degeneration

Status:
Terminated

Trial end date:
2020-04-24

Target enrollment:

Participant gender:

Summary

Age-related macular degeneration (AMD) is the leading cause of blindness among adults in North America. The current standard of care for patients with exudative ("wet") AMD is anti-vascular endothelial growth factor (anti-VEGF) therapy which must be administered by an injection into the eye every 4-8 weeks. MT-0814 is being developed for the treatment of patients with exudative AMD, and could offer an alternative, safer and less burdensome therapy.

Phase:

Phase 2

Details

Lead Sponsor:

Senju Pharmaceutical Co., Ltd.

Collaborator:

PPD